VivoSim Labs (VIVS) Common Equity (2010 - 2026)
VivoSim Labs (VIVS) posted quarterly Common Equity of -$1.1 million for Q1 2026, down 110.47% year-over-year from $10.5 million in Q1 2025, and down 124.75% quarter-over-quarter from $4.4 million in Q4 2025.
VivoSim Labs (VIVS) Common Equity (2010 - 2026) Analysis & Trends
VivoSim Labs' Common Equity history runs 17 years deep, the most recent figure standing at -$1.1 million for Q1 2026.
- In Q1 2026, Common Equity fell 110.47% year-over-year to -$1.1 million; the TTM figure through Mar 2026 stood at -$1.1 million (down 110.47% YoY), while the FY2026 annual figure was -$1.1 million, down 110.47% from the prior year.
- Common Equity for Q1 2026 stood at -$1.1 million, down from $4.4 million in the prior quarter.
- The five-year high for Common Equity was $30.2 million in Q1 2022, with the low at -$1.1 million in Q1 2026.
- The 5-year median for Common Equity is $8.5 million (2023), against an average of $11.3 million.
- The sharpest annual moves came in 2025 and 2026: Common Equity surged 1120.05% in 2025, then slumped 110.47% in 2026.
- VivoSim Labs' Common Equity stood at $22.3 million in 2022, then plunged by 72.26% to $6.2 million in 2023, then slumped by 94.11% to $364000.0 in 2024, then soared by 1120.05% to $4.4 million in 2025, then slumped by 124.75% to -$1.1 million in 2026.
- Business Quant data shows VIVS's Common Equity at -$1.1 million in Q1 2026, $4.4 million in Q4 2025, and $7.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - | -2.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.35 Mn |
| Mar 31, 2026 | -1.10 Mn |
| Dec 31, 2025 | 4.44 Mn |
| Sep 30, 2025 | 7.07 Mn |
| Jun 30, 2025 | 9.54 Mn |
| Mar 31, 2025 | 10.49 Mn |
| Dec 31, 2024 | 364,000.00 |
| Sep 30, 2024 | 3.68 Mn |
| Jun 30, 2024 | 6.66 Mn |
| Mar 31, 2024 | 3.60 Mn |
| Dec 31, 2023 | 6.18 Mn |
| Sep 30, 2023 | 8.46 Mn |
| Jun 30, 2023 | 11.78 Mn |
| Mar 31, 2023 | 15.33 Mn |
| Dec 31, 2022 | 22.29 Mn |
| Sep 30, 2022 | 25.01 Mn |
| Jun 30, 2022 | 27.65 Mn |
| Mar 31, 2022 | 30.21 Mn |
| Dec 31, 2021 | 31.29 Mn |
| Sep 30, 2021 | 34.21 Mn |